secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2026-06-15T11:05:59+00:00
Accession:  0001193125-26-270275
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo finalizes SUNRISE-FA 2 pivotal trial for LX2006 in FA cardiomyopathy; BLA submission expected H1 2028
--------------------------------------------------------------------------------

- Open-label pivotal trial of LX2006: 13 treated vs 13 untreated control; primary endpoint LVMI at 6 months.
- BLA submission under accelerated approval on track for H1 2028; topline data readout expected H2 2027.
- FDA removed co-primary endpoint of cardiac frataxin protein expression; trial powered for LVMI effect size ≥15%.
- Pediatric cohorts included; untreated control participants eligible to cross over to LX2006 after 6 months.
- CLARITY-FA natural history study ongoing, shares inclusion criteria; first patient enrollment by end of June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526270275/0001193125-26-270275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526270275/lxeo-20260615.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-270275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer